The short answer
In October 2025 the MHRA's Criminal Enforcement Unit dismantled what it described as the first illicit weight-loss medicine manufacturing facility found in the UK, at an industrial warehouse near Northampton, seizing more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch.
Key facts
- Announced
- 24 October 2025, gov.uk
- Location
- Industrial estate near Northampton
- Seized
- 2,000+ unlicensed retatrutide and tirzepatide pens
- Also seized
- Tens of thousands of empty pens
- Plus
- Raw ingredients, packaging and manufacturing equipment
- Cash
- Approximately £20,000
- Street value of finished goods
- More than £250,000
- Assisted by
- Northamptonshire Police
What was found
According to the MHRA's published account, officers seized tens of thousands of empty weight-loss pens ready to be filled, raw chemical ingredients, sophisticated packaging and manufacturing equipment, approximately £20,000 in cash, and more than 2,000 unlicensed retatrutide and tirzepatide pens already awaiting dispatch to customers.
Why the empty pens matter most
Tens of thousands of empty devices is a statement about intended scale. Finished product represents what had been made; empty pens represent capacity. The MHRA described the site as used for large-scale manufacture, packaging and distribution, and the ratio between the two figures is what supports that description.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The word that matters in the description
Pens. What was seized were finished dosage forms: devices filled, packaged and labelled for human injection, presented as medicines. That is a manufactured medicinal product supplied without authorisation, which is what the Human Medicines Regulations 2012 prohibit, and it is categorically different from unformulated material supplied for laboratory research.
Why retatrutide specifically
It is investigational and approved nowhere, which means no legitimate pen exists anywhere in the world. A tirzepatide pen at least has a real counterpart that a counterfeit imitates. A retatrutide pen has no authorised version to be a copy of. Whatever is inside it has no reference product, no assessed manufacturing standard and no way for a recipient to establish what they received.
What the MHRA said
Andy Morling, head of the Criminal Enforcement Unit, was quoted describing the operation as a landmark result and warning that people should be extremely cautious when buying medicines online. The agency described it as believed to be the largest single seizure of trafficked weight-loss medicines recorded by any law enforcement agency.
Where this site stands relative to it
Material supplied here is unformulated compound for laboratory research. It is not a pen, not a filled device, not packaged or labelled for human administration, and not presented as a medicine. That distinction is exactly what the enforcement framework turns on, and it is why this site publishes no dosing, no protocols and no therapeutic claims of any kind.
Frequently asked questions
What was seized in Northampton?
Over 2,000 unlicensed retatrutide and tirzepatide pens, tens of thousands of empty pens, raw ingredients, manufacturing equipment and around £20,000 in cash.
Why is a retatrutide pen particularly concerning?
Retatrutide is approved nowhere, so no legitimate pen exists. There is no authorised reference product for a recipient to compare against.
How does this differ from research material?
A pen is a finished dosage form packaged for human injection and presented as a medicine. That is what the Human Medicines Regulations prohibit supplying without authorisation.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- The Scale of UK Medicines EnforcementAlmost 20 million doses and nearly £45m of illegal medicines seized in 2025, including more than 5,000 illegally traded GLP-1 products.
- The EMA Opinion on Oral Semaglutide for Weight ManagementOn 21 May 2026 the CHMP recommended adding oral tablets to Wegovy's authorisation in four strengths. What a positive opinion is, and what it is not.
- MARITIME: Where the Monthly Compound Is Being TestedMaridebart cafraglutide's Phase 3 programme spans obesity, sleep apnoea and heart failure - including a 5,056-participant cardiology trial.
- Reading a Programme From Its Trial RegistrationsOne trial was withdrawn with zero enrolment; three others are completed, active or recruiting. Withdrawn and terminated mean different things.
- What the Systematic Reviews Say About Children and AdolescentsTwo 2025 systematic reviews assessed GLP-1 agonists in children and adolescents. What review-level evidence establishes, and what is still missing.